Catalyst Pharmaceuticals (CPRX)
(Delayed Data from NSDQ)
$20.07 USD
+0.31 (1.57%)
Updated Sep 16, 2025 04:00 PM ET
After-Market: $20.07 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth D Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Catalyst Pharmaceuticals, Inc. has a PEG ratio of 0.66 compared to the Medical - Drugs industry's PEG ratio of 1.37.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CPRX 20.07 +0.31(1.57%)
Will CPRX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CPRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CPRX
Catalyst Pharmaceutical (CPRX) is a Top-Ranked Value Stock: Should You Buy?
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
CPRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock
Catalyst Pharmaceuticals Settles Firdapse Patent Litigation With Lupin
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock
Other News for CPRX
Directional Movement Crossover Bearish appears for CPRX after 1.05% move
CPRX Fell Below 20 Day Moving Average on September 12
Crossed Above 20 Day Moving Average appears for CPRX after 2.58% move
Bank of America Securities Sticks to Their Buy Rating for Catalyst Pharma (CPRX)
CPRX forms 20 Day Moving Average Resistance on September 10